소화관 치료제 시장 : 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Gastrointestinal Therapeutics Market was valued at USD 42.5 billion in 2024 and is estimated to grow at a CAGR of 5.9% to reach USD 74.8 billion by 2034. This market expansion is largely driven by the rising prevalence of gastrointestinal (GI) disorders, such as inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and peptic ulcer disease. As the adult population continues to expand, the incidence of chronic GI conditions is also on the rise, creating a larger patient base and increasing demand for specialized treatments. Untreated GI conditions can lead to severe complications, including colorectal cancer and toxic megacolon, particularly in cases like ulcerative colitis. These trends highlight the need for effective, long-term therapies, fueling the demand for advanced treatment options such as biologics and targeted therapies.

The development of biologics and biosimilars has played a critical role in accelerating market growth. These therapies have proven to be highly effective in managing GI disorders by providing targeted treatments that control inflammation and help maintain long-term remission. Increased investment in research and development (R&D), along with a steady stream of regulatory approvals, has driven innovation in the field. Additionally, improved public awareness of GI health, advancements in diagnostic tools, and the expansion of healthcare access in emerging economies have made these treatments more available to a broader population, further supporting market growth.

The biologics and biosimilars segment was valued at USD 19.6 billion in 2024 and is expected to reach USD 36.1 billion by 2034, growing at a CAGR of 6.4%. These treatments have become the preferred option for managing conditions like Crohn's disease and ulcerative colitis. Biologics offer a targeted approach to inflammation control, while biosimilars have increased access to these therapies by lowering the cost of treatment, making them more affordable for patients worldwide. The recent approval of biosimilars for key drugs has further contributed to the growing accessibility of advanced treatments.

In 2024, the adult segment generated USD 26.3 billion and is projected to maintain its dominant position, growing at a CAGR of 5.6% through 2034. The adult population is especially vulnerable to chronic gastrointestinal (GI) conditions like Crohn's disease, ulcerative colitis, GERD, and other related disorders. This increased prevalence is largely driven by modern lifestyle factors, such as poor dietary choices, high stress levels, and sedentary habits, all of which contribute to a rise in GI issues that require long-term medical care. To meet the growing demand, pharmaceutical companies are advancing the development of targeted drug formulations and delivery methods, including injectables and sustained-release tablets, aimed at improving treatment efficacy and enhancing patient compliance.

North America Gastrointestinal Therapeutics Market generated USD 17.8 billion in 2024 and is expected to generate USD 30.7 billion by 2034, growing at a CAGR of 5.6%. North America's strong market position is attributed to its advanced healthcare infrastructure, high awareness of digestive health, and widespread access to modern treatment options. The presence of leading pharmaceutical companies, along with ongoing innovation and research efforts, continues to drive the market. Collaborative partnerships between biotech firms and research institutions further accelerate the development and availability of novel therapies, ensuring that North America remains a key player in the global GI therapeutics market.

Notable companies involved in the Global Gastrointestinal Therapeutics Market include Takeda Pharmaceutical, GlaxoSmithKline, Eli Lilly and Company, Johnson & Johnson, Cipla, AstraZeneca, Biogen, Pfizer, Bayer, Sanofi, Sun Pharma, AbbVie, Phathom Pharmaceuticals, and Dr. Reddy's Laboratories. Leading companies in the gastrointestinal therapeutics market are focusing on expanding their product portfolios through innovation in biologics and biosimilars. Many are investing in cutting-edge research to develop more effective treatments that address the underlying causes of GI disorders. Partnerships with research institutions and biotech firms are also a common strategy to accelerate drug development and commercialization. Additionally, companies are prioritizing geographical expansion, particularly in emerging markets, by making treatments more accessible and affordable.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Drug type
  • 2.2.3 Disease type
  • 2.2.4 Medication type
  • 2.2.5 Age group
  • 2.2.6 Route of administration
  • 2.2.7 Distribution channel
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of gastrointestinal diseases
    • 3.2.1.2 Growing advancements in drug development
    • 3.2.1.3 Increasing awareness and preventive care measures for gastrointestinal health
    • 3.2.1.4 Increased R&D investment and activities
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse effects of medication
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing interest in gut microbiome research
    • 3.2.3.2 Digital health platforms are improving access to GI treatments
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Future market trends
• 3.7 Porter’s analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Antidiarrheals
• 5.3 Laxatives
• 5.4 Biologics/ biosimilars
• 5.5 Antiemetics
• 5.6 Antiulcer agents
• 5.7 Antibiotics
• 5.8 Antacids
• 5.9 Proton pump inhibitors (PPIs)
• 5.10 Other drug types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Inflammatory bowel disease (IBD)
  • 6.2.1 Crohn's disease
  • 6.2.2 Ulcerative colitis
• 6.3 Gastroesophageal reflux disease (GERD)
  • 6.3.1 Stage 1
  • 6.3.2 Stage 2
  • 6.3.3 Stage 3
  • 6.3.4 Stage 4
• 6.4 Peptic ulcer disease
• 6.5 Irritable bowel syndrome (IBS)
  • 6.5.1 IBS-D
  • 6.5.2 IBS-C
  • 6.5.3 IBS-M
• 6.6 Other disease types

Chapter 7 Market Estimates and Forecast, By Medication Type, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Branded
• 7.3 Generics

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Pediatric
• 8.3 Adult
• 8.4 Geriatric

Chapter 9 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Oral
• 9.3 Parenteral

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 Hospital pharmacies
• 10.3 Retail pharmacies
• 10.4 Online pharmacies

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Argentina
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE

Chapter 12 Company Profiles

• 12.1 AbbVie
• 12.2 AstraZeneca
• 12.3 Bayer
• 12.4 Biogen
• 12.5 Cipla
• 12.6 Dr. Reddy’s Laboratories
• 12.7 Eli Lilly and Company
• 12.8 GlaxoSmithKline
• 12.9 Glenmark Pharmaceuticals
• 12.10 Johnson & Johnson
• 12.11 Novo Nordisk
• 12.12 Pfizer
• 12.13 Phathom Pharmaceuticals
• 12.14 Sanofi
• 12.15 Sun Pharma
• 12.16 Takeda Pharmaceutical